TCL Archive Nobel Laureate Gilman Prepares to Leave The Texas Cancer Agency—Can it Survive? September 28, 2012
TCL Archive Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says September 26, 2014